A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease

Trial Profile

A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 18 Sep 2017 Results assessing safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory chronic graft versus host disease, were published in the Blood.
    • 02 Aug 2017 Results published in a Janssen Biotech media release.
    • 02 Aug 2017 According to the Food and Drug Administration media release, the U.S. Food and Drug Administration has approved Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments. Approval was based on results of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top